Poor targeting of therapeutics leading to severe adverse effects on normal tissues is
considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug …

Loss of the tumor suppressor gene CDKN2A, encoding p16 and p14, is a frequent event
driving melanoma progression. Therefore, therapeutic strategies aimed at CDKN2A loss …

Somatic copy number alterations (SCNAs), generally losses containing interferons and
interferon-pathway genes, many on chromosome 9p, predict immune-cold, immune …

The tumor microenvironment (TME) is a dynamic pseudoorgan that shapes the development
and progression of cancers. It is a complex ecosystem shaped by interactions between …

Background There remains a paucity of data regarding the efficacy of immune checkpoint
therapy (ICT) combinations±vascular endothelial growth factor (VEGF) targeted therapy (TT) …

Small molecules capable of modulating methionine adenosyltransferase 2A (MAT2A) are of
significant interest in precise cancer therapeutics. Herein, we raised the hole–electron …

Cisplatin-based chemotherapy has been the standard of care in metastatic urothelial cancer
(mUC) for more than two decades. However, many patients with comorbidities cannot …

Background Accurate diagnosis of pancreatic lesions by endoscopic ultrasound‐guided fine‐
needle aspiration (EUS‐FNA) or fine‐needle biopsy can be challenging. Although surrogate …

The methionine salvage pathway is responsible for recycling sulfur-containing metabolites
to methionine. This salvage pathway has been found to be implicated in cell apoptosis …

Background When urothelial carcinoma of the bladder (UCB) presents or progresses to
chemo-refractory metastatic disease, the search for new therapeutic targets is paramount …